Lymphoplasmacytic Lymphoma with IgG or IgA Paraprotein: A Study of 29 Cases including Cases that Can Mimic Plasma Cell Neoplasms.

[1]  A. Panizo,et al.  Concomitant lymphoplasmacytic lymphoma, multiple myeloma, and amyloidosis: A diagnostic and therapeutic challenge , 2022, Clinical case reports.

[2]  B. Sander,et al.  Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study , 2021, British journal of haematology.

[3]  T. Liehr.  International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts , 2021, Cytogenetic and Genome Research.

[4]  S. Treon,et al.  A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia , 2020, Leukemia & lymphoma.

[5]  P. Lin,et al.  Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis. , 2019, Pathology.

[6]  L. Baldini,et al.  Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network , 2019, American journal of hematology.

[7]  Z. Estrov,et al.  Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments , 2019, British journal of haematology.

[8]  L. Medeiros,et al.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma , 2017, Modern Pathology.

[9]  M. Zimmerman,et al.  Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge. , 2017, American journal of blood research.

[10]  K. Patel,et al.  Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. , 2016, Clinical lymphoma, myeloma & leukemia.

[11]  R. Kyle,et al.  Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. , 2016, American journal of clinical pathology.

[12]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[13]  K. Young,et al.  Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression , 2016, Leukemia & lymphoma.

[14]  C. Dinardo,et al.  Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies , 2015, Modern Pathology.

[15]  W. Morice,et al.  Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B‐cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B‐cell process , 2015, British journal of haematology.

[16]  L. Medeiros,et al.  Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study , 2013, Cytometry. Part B, Clinical cytometry.

[17]  E. Kulbacki,et al.  Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. , 2012, Human Pathology.

[18]  T. Molina,et al.  Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. , 2011, American journal of clinical pathology.

[19]  L. Medeiros,et al.  Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. , 2005, American journal of clinical pathology.

[20]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.